Gencurix Inc. (KOSDAQ:229000)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,638.00
+40.00 (2.50%)
Aug 28, 2025, 3:30 PM KST
2.50%
Market Cap25.76B
Revenue (ttm)3.39B
Net Income (ttm)-12.55B
Shares Out16.12M
EPS (ttm)-877.76
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume110,407
Average Volume46,490
Open1,605.00
Previous Close1,598.00
Day's Range1,561.00 - 1,718.00
52-Week Range1,131.00 - 3,420.00
Beta0.74
RSI50.32
Earnings DateAug 11, 2025

About Gencurix

Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detection. The company has a strategic alliance with Qiagen N.V. for the development of oncology assays for use on the QIAcuityDx platform. The company was fo... [Read more]

Industry Medical - Specialties
Sector Healthcare
Founded 2011
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 229000
Full Company Profile

Financial Performance

In 2023, Gencurix's revenue was 2.60 billion, an increase of 1.60% compared to the previous year's 2.56 billion. Losses were -19.26 billion, -21.70% less than in 2022.

Financial Statements

News